Skip to main content
Premium Trial:

Request an Annual Quote

Curidium Lands $5M in Share Offering, Plans to Push Mental Health Dx

NEW YORK (GenomeWeb News) - Curidium Medica said today that it has grossed £2.5 million ($5.1 million) through the sale of 100 million shares at a price of 2.5 pence per share.
 
The London-based company said it plans to use the proceeds from the stock sale to fund product and business development programs. Part of the new capital will feed new R&D and business development programs for Curidium’s PsychINDx test, a blood-based diagnostic that categorizes patients with schizophrenia/bipolar disorder into four subgroups.
 
The company said the test is expected to support the development of new drug treatments targeted for the different subgroups.
 
The test runs on the company’s Homomatrix analysis tool, which uses pattern-recognition algorithms to analyze large sets of gene expression and other biological data from heterogenous populations, according to Curidium’s website.
 
The financing "will help accelerate the company's development in the personalized medicine space over the near term,” said company executive chairman Gosse Bruinsma in a statement.
 
The company said the lead investor in the offering will receive options to buy 5 million ordinary shares at 2.5 pence that may be exercised over the next five years.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.